« Back

Karl E. Anderson, M.D.
Professor, Division of Gastroenterology and Hepatology



Karl E. Anderson, M.D.

Karl E. Anderson, M.D.
Professor of Preventive Medicine and Community Health
Internal Medicine, and Pharmacology and Toxicology

University of Texas Medical Branch
301 University Blvd.
Galveston, TX 77555-1109
Phone: 409.772.1501
Fax: 409.772.4789
kanderso@utmb.edu

Biosketch

A graduate of the Johns Hopkins University School of Medicine, Dr. Anderson completed his residency and postgraduate training in gastroenterology at the New York Hospital-Cornell Medical Center. He was a member of the faculty at the Rockefeller University, Cornell University Medical College and New York Medical College before coming to UTMB in 1987. He directs the Division of Human Nutrition in the Department of Preventive Medicine and Community Health, and is an active clinical investigator particularly on the General Clinical Research Center (GCRC), where he is also Associate Program Director. He is PI for UTMB's NIH K30 grant that supports a variety of clinical research education programs, Director of the Clinical Research Education Office, and Director of the Graduate Program (PhD or MS) in Clinical Science, which is suited particularly for physicians seeking advanced training in clinical research.

Research Interests

Dr. Anderson's research interests include (i) pathogenesis of human porphyrias and identification of factors that increase susceptibility; (ii) development of new therapies for porphyrias; (iii) effects of diet on drug metabolism in humans, especially by cytochrome P450 enzymes, and on circulating hormone levels; (iv) collaborative work on effects of soy feeding in humans on breast cancer risk.

Clinical Interests

Dr. Anderson clinical interests include human porphyrias, metabolic and nutritional aspects of liver disease, and general clinical gastroenterology and hepatology.

Selected Publications

  • Egger NE, Goeger DE, Payne DA, Miskovsky EP, Weinman SA, Anderson KE. Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C and inherited uroporphyrinogen decarboxylase deficiency. Digestive Diseases and Sciences 2002; 47:419-426.
  • Anderson KE, Bloomer JR, Bonkovsky HL, Kushner JP, Pierach CA, Pimstone NR, Desnick RJ: Recommendations for the diagnosis and treatment of the acute porphyrias. Annals of Internal Medicine 2005;142:439-50.
  • Huang Y, Cao S, Nagamani M, Anderson KE, Grady J, Lu L-JW: Decreased circulating levels of tumor necrosis factor-alpha (TNF-a) in postmenopausal women during consumption of soy containing isoflavones. Journal of Clinical Endocrinology and Metabolism 2005;90:3956-62.
  • Nhan S, Anderson KE, Nagamani M, Grady JJ, Lu LJ: Effect of a soymilk supplement containing isoflavones on urinary f2 isoprostane levels in premenopausal women. Nutrition and Cancer 2005;53(1):73-81.
  • Akagi R, Kato N, Inoue R, Anderson KE, Jaffe EK, Sassa S: delta-Aminolevulinate dehydratase (ALAD) porphyria: The first case in North America with two novel ALAD mutations. Molecular Genetics and Metabolism. 2006:87:329-336.
  • Akagi R, Inoue R, Muranaka S, Tahara T, Taketani S, Anderson KE, Phillips JD, Sassa S. Dual gene defects involving d-aminolaevulinate dehydratase and coproporphyrinogen oxidase in a porphyria patient. British Journal of Haematology. 2006;132:237-243.
  • Anderson KE, Collins S. Open-label study of hemin for acute porphyria: clinical practice implications. American Journal of Medicine. 2006;119:19-24.
  • Anderson KE: The porphyrias (Chapter 72), in Boyer T, Wright T, Manns M (eds): Zakim and Boyer's Hepatology: A Textbook of Liver Diseases. Philadelphia, Elsevier, 2006, pp 1391-1432. 9.
  • Anderson KE, Porphyria cutanea tarda – a possible role for ascorbic acid (Editorial) Hepatology, 2007;45(1):6-8. 10.
  • Madan P, Schaaf CP, Vardhan P, Bhayana S, Chandra P, Anderson KE: Hans Gunther and his disease. Photodermatol Photoimmunol Photomed 2007;23(6):261-3.
  • Desnick RJ, Astrin KH, Anderson KE. Heme biosynthesis and the porphyrias (Chapter 28). In: Suchy, FJ, Sokol, R,J, Balistreri, WF, eds. Liver Disease in Children, 3rd edition. Cambridge: Cambridge University Press, 2007, pp 677-693.
  • Anderson KE. The porphyrias (Chapter 223). In: L. Goldman and D. Ausiello., eds. Cecil Textbook of Medicine, 23rd edition, Philadelphia, W.B. Saunders Co., 2007, pp 1585-1593.

»Pub Med Search

The department of internal medicine is developing evidence based clinical protocols which will be available in EPIC (as order sets) for use when admitting patients with these diagnoses. Their AIM is to standardize care and decrease length of stay and readmission rates.

Currently available protocols are:
  • CAP - Community Acquired Pneumonia Orderset
  • Congestive Heart Failure (CHF)
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Diabetic Ketoacidosis Adult, ICU
  • General Medicine Admission
  • Immunodeficiency Flow Panel
  • MICU/CCU Admission Order Set
  • Oral Analgesic Medicaitons
  • Parenteral Opioids
  • Sepsis, Adult ICU
  • 111 - Stroke Alert
  • 112 - Stroke Activation
  • 300086 - Stroke Floor Admission
  • 3000000001 -  Stroke Critical care without tPA
  • 300088 Stroke - Transfer from Critical care to floor
  • 3004002 - Stroke Discharge

All protocols can be found in the EPIC order set section.

» For more information

Meaning Use logo

The department of Internal Medicine has a large role in the Meaningful Use Initiative. Our participation is key for the success of the initiative. Please visit the meaningful use website for important communication and updates from the Meaningful Use Initiative.

Site Managed by UTMB Information Design Services.